Pomalidomide: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), DMC (Denmark) and G-BA (Germany), among others, recommended or restricted pomalidomide, while AWMSG (Wales) did not recommend it.
Assessment has run over 11.4 years, from 8 Jan 2014 at HAS (France) to 15 Jun 2025 at NYE METODER (Norway).
No assessment is on file from TLV (Sweden) and CIPM (Spain), each among the eight highest-volume agencies here.
Not every gap is a refusal: for pomalidomide, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 2 of 24 records date from 2023 or later.
The programme is broad: 9 distinct indication wordings are recorded for pomalidomide by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
6 of these 24 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess pomalidomide, on 8 Jan 2014; NYE METODER (Norway) did not open a file until 15 Jun 2025 — an unusually long tail of 11.4 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 9 years in total.
7 of the 10 agencies here assessed pomalidomide more than once, PBAC (Australia) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for pomalidomide.
The full ledger for pomalidomide reads 14 recommended, 3 restricted, 1 no benefit and 1 terminated, with 5 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 15 Jun 2025 | Kombinasjon med deksametason ved myelomatose for behandling av pasienter som har fått minst to tidligere behandlingsregi… | introduced | source |
| PHARMAC (New Zealand) | 3 Aug 2021 | multiple myeloma, relapsed or refractory, 3rd line with dexamethasone | PTAC advice: Low · decision reached | source |
| AOTMIT (Poland) | 5 May 2021 | Imnovid reimbursement recommendation | recommended conditionally | source |
| HAS (France) | 19 Feb 2020 | Indication extension | SMR substantial · ASMR V | source |
| PBAC (Australia) | 2017 | Relapsed/refractory multiple myeloma (RRMM) | The PBAC rejected the request to amend the current restriction for pomalidomide to include… | source |
19 further decisions for pomalidomide, across 8 agencies, are not shown here. They link to 12 further source documents.
Related molecules
- selinexor — divergent outcome (recommended vs not recommended) on a shared indication
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
Coverage: 24 decisions for pomalidomide from 10 agencies, 2014 to 2025. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.